Nada Aboelella

Dr. Nada Aboelella

Graduate Research Assistant, Georgia Cancer Center, Medical College of Georgia, Augusta University
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Nada AboelellaNada Aboelella
Nada Aboelella
CBCaitlin Brandle
Caitlin Brandle
TKTimothy Kim
Timothy Kim
ZDZhi-Chun Ding
Zhi-Chun Ding
GZGang Zhou
Gang Zhou
It has been well-established that cancer cells are under constant oxidative stress, as reflected by elevated basal level of reactive oxygen species (ROS), due to increased metabolism driven by aberrant cell growth. Cancer cells can adapt to maintain redox homeostasis through a variety of mechanisms. The prevalent perception about ROS is that they are one of the key drivers promoting tumor initiation, progression, metastasis, and drug resistance. Based on this notion, numerous antioxidants that aim to mitigate tumor oxidative stress have been tested for cancer prevention or treatment, although the effectiveness of this strategy has yet to be established. In recent years, it has been increasingly appreciated that ROS have a complex, multifaceted role in the tumor microenvironment (TME), and that tumor redox can be targeted to amplify oxidative stress inside the tumor to cause tumor destruction. Accumulating evidence indicates that cancer immunotherapies can alter tumor redox to intensify tumor oxidative stress, resulting in ROS-dependent tumor rejection. Herein we review the recent progresses regarding the impact of ROS on cancer cells and various immune cells in the TME, and discuss the emerging ROS-modulating strategies that can be used in combination with cancer immunotherapies to achieve enhanced antitumor effects.

8 October 2020 in Science Immunology
Verified
Journal Article
Closed access
ZDZhi-Chun Ding
Zhi-Chun Ding
HSHuidong Shi
Huidong Shi
Nada AboelellaNada Aboelella
Nada Aboelella
KFKateryna Fesenkova
Kateryna Fesenkova
EPEun-Jeong Park
Eun-Jeong Park
GZGang Zhou
Gang Zhou
Persistent STAT5 activation endows antitumor CD4 + T cells with desirable functional features that optimize adoptive T cell therapy.

17 June 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
GPGary Piazza
Gary Piazza
AWAntonio Ward
Antonio Ward
XCXi Chen
Xi Chen
YMYulia Y. Maxuitenko
Yulia Y. Maxuitenko
ACAlex Coley
Alex Coley
GZGang Zhou
Gang Zhou

25 January 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
ZDZhi-Chun Ding
Zhi-Chun Ding
Nada AboelellaNada Aboelella
Nada Aboelella
LBLocke Bryan
Locke Bryan
HSHuidong Shi
Huidong Shi
GZGang Zhou
Gang Zhou
Cyclophosphamide (CTX) is a major component of the chemotherapy conditioning regimens used in the clinic to prepare cancer patients for hematopoietic stem cell transplantation or adoptive T cell therapy. Previous studies have shown that CTX given at nonmyeloablative doses in mice and patients leads to expansion of myeloid cells within which the monocytic subset exhibits immunosuppressive activity. However, the ontogeny and gene expression signature of these CTX-induced monocytes are not well-defined. Here, we report that the expansion of myeloid cells is a default process intrinsic to hematopoietic recovery after chemotherapy. During this process, the monocytes repopulated in mice acquire immunosuppressive activity, which can persist long after cessation of chemotherapy. Moreover, monocytes acquire a gene signature characteristic of neutrophil precursors, marked by increased proliferative capability and elevated expressions of multiple primary and secondary granules. We provide evidence that CTX-induced myeloid cell expansion is regulated by DNA methyltransferase 1 (Dnmt1) and dependent on chemotherapy-induced microbial translocation. These findings help advance our understanding of the differentiation, heterogeneity, and function of myeloid cells repopulating after chemotherapy.

26 July 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
Nada AboelellaNada Aboelella
Nada Aboelella
CBCaitlin Brandle
Caitlin Brandle
OOOgacheko Okoko
Ogacheko Okoko
YGYeashin Gazi
Yeashin Gazi
ZDZhi-Chun Ding
Zhi-Chun Ding
GZGang Zhou
Gang Zhou
Background: Adoptive cell therapy (ACT) using genetically modified T cells has evolved into a promising treatment option for patients with cancer. However, even for the best-studied and clinically validated CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, many patients face the challenge of lack of response or occurrence of relapse. There is increasing need to improve the efficacy of ACT so that durable, curative outcomes can be achieved in a broad patient population. Methods: Here, we investigated the impact of indomethacin (indo), a non-steroidal anti-inflammatory drug (NSAID), on the efficacy of ACT in multiple preclinical models. Mice with established B-cell lymphoma received various combinations of preconditioning chemotherapy, infusion of suboptimal dose of tumor-reactive T cells, and indo administration. Donor T cells used in the ACT models included CD4+ T cells expressing a tumor-specific T cell receptor (TCR) and T cells engineered to express CD19CAR. Mice were monitored for tumor growth and survival. The effects of indo on donor T cell phenotype and function were evaluated. The molecular mechanisms by which indo may influence the outcome of ACT were investigated. Results: ACT coupled with indo administration led to improved tumor growth control and prolonged mouse survival. Indo did not affect the activation status and tumor infiltration of the donor T cells. Moreover, the beneficial effect of indo in ACT did not rely on its inhibitory effect on the immunosuppressive cyclooxygenase 2 (COX2)/prostaglandin E2 (PGE2) axis. Instead, indo-induced oxidative stress boosted the expression of death receptor 5 (DR5) in tumor cells, rendering them susceptible to donor T cells expressing TNF-related apoptosis-inducing ligand (TRAIL). Furthermore, the ACT-potentiating effect of indo was diminished against DR5-deficient tumors, but was amplified by donor T cells engineered to overexpress TRAIL. Conclusion: Our results demonstrate that the pro-oxidative property of indo can be exploited to enhance death receptor signaling in cancer cells, providing rationale for combining indo with genetically modified T cells to intensify tumor cell killing through the TRAIL-DR5 axis. These findings implicate indo administration, and potentially similar use of other NSAIDs, as a readily applicable and cost-effective approach to augment the efficacy of ACT.

23 May 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
RLRosy Liao
Rosy Liao
JHJocelyn Y. Hsu
Jocelyn Y. Hsu
Nada AboelellaNada Aboelella
Nada Aboelella
JMJoshua A. McKeever
Joshua A. McKeever
ATAnika T. Thomas-Toth
Anika T. Thomas-Toth
JLJames L. LaBelle
James L. LaBelle
The specific BCL-2 small molecule inhibitor venetoclax induces apoptosis in a wide range of malignancies, which has led to rapid clinical expansion in its use alone and in combination with chemotherapy and immune-based therapies against a myriad of cancer types. While lymphocytes, and T cells in particular, rely heavily on BCL-2 for survival and function, the effects of small molecule blockade of the BCL-2 family on surviving immune cells is not fully understood. We aimed to better understand the effect of systemic treatment with venetoclax on regulatory T cells (Treg), which are relatively resistant to cell death induced by specific drugging of BCL-2 compared to other T cells. We found that BCL-2 blockade altered Treg transcriptional profiles and mediated Treg plasticity toward a TH17-like Treg phenotype, resulting in increased IL17A production in lymphoid organs and within the tumor microenvironment. Aligned with previously described augmented antitumor effects observed when combining venetoclax with anti–PD-1 checkpoint inhibition, we also demonstrated that Treg-specific genetic BCL-2 knockout combined with anti–PD-1 induced tumor regression and conferred overlapping genetic changes with venetoclax-treated Tregs. As long-term combination therapies using venetoclax gain more traction in the clinic, an improved understanding of the immune-modulatory effects caused by venetoclax may allow expansion of its use against malignancies and immune-related diseases.